

Michael Weller

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3232536/michael-weller-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

758
papers

74,217
citations

114
h-index

259
g-index

824
ext. papers

89,553
ext. citations

6.5
avg, IF

7.66
L-index

#	Paper	IF	Citations
758	Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. <i>New England Journal of Medicine</i> , 2005 , 352, 987-96	59.2	13703
757	MGMT gene silencing and benefit from temozolomide in glioblastoma. <i>New England Journal of Medicine</i> , 2005 , 352, 997-1003	59.2	5267
756	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. <i>Lancet Oncology, The</i> , 2009 , 10, 459-66	21.7	5111
755	An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. <i>Nature</i> , 2011 , 478, 197-203	50.4	1185
754	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018 , 555, 469-474	50.4	992
753	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 2306-2316	27.4	875
752	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. <i>Acta Neuropathologica</i> , 2009 , 118, 469-74	14.3	874
751	Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 707-15	21.7	792
750	Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. <i>Nature Medicine</i> , 2002 , 8, 808-15	50.5	698
749	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1100-8	21.7	629
748	NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5874-80	2.2	625
747	Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4189-99	2.2	625
746	Long-term survival with glioblastoma multiforme. <i>Brain</i> , 2007 , 130, 2596-606	11.2	624
745	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology, The</i> , 2017 , 18, e315-e329	21.7	599
744	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. <i>Acta Neuropathologica</i> , 2010 , 120, 707-18	14.3	596
743	MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. <i>Nature Reviews Neurology</i> , 2010 , 6, 39-51	15	538
742	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1373-1385	21.7	518

741	EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. <i>Lancet Oncology, The</i> , 2014 , 15, e395-403	21.7	498
740	Current state of immunotherapy for glioblastoma. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 422-442	19.4	466
739	Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5743-50	2.2	464
738	Standards of care for treatment of recurrent glioblastoma--are we there yet?. <i>Neuro-Oncology</i> , 2013 , 15, 4-27	1	432
737	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology, The</i> , 2015 , 16, e534-e542	21.7	425
736	Lomustine and Bevacizumab in Progressive Glioblastoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1954-1963	59.2	425
735	High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. <i>Lancet Oncology, The</i> , 2010 , 11, 1036-47	21.7	417
734	EANO guidelines for the diagnosis and treatment of meningiomas. <i>Lancet Oncology, The</i> , 2016 , 17, e383-391	21.7	414
733	Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. <i>Lancet Oncology, The</i> , 2008 , 9, 29-38	21.7	407
732	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 1199-208	1	398
731	Glioma. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15017	51.1	368
730	Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1168-74	2.2	367
729	cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". <i>Acta Neuropathologica</i> , 2018 , 136, 805-810	14.3	367
728	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. <i>Neuro-Oncology</i> , 2015 , 17, 1064-75	1	356
727	SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. <i>Cancer Research</i> , 2004 , 64, 7954-61	10.1	347
726	Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2712-8	2.2	338
725	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology, The</i> , 2017 , 18, 682-694	21.7	336
724	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 1003-1010	13.4	328

723	Advances in the molecular genetics of gliomas - implications for classification and therapy. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 434-452	19.4	320
722	Current concepts and management of glioblastoma. <i>Annals of Neurology</i> , 2011 , 70, 9-21	9.4	319
721	MGMT testing--the challenges for biomarker-based glioma treatment. <i>Nature Reviews Neurology</i> , 2014 , 10, 372-85	15	316
720	Changing paradigms--an update on the multidisciplinary management of malignant glioma. <i>Oncologist</i> , 2006 , 11, 165-80	5.7	316
719	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. <i>Acta Neuropathologica</i> , 2015 , 129, 133-46	14.3	313
718	Caspases as treatment targets in stroke and neurodegenerative diseases. <i>Annals of Neurology</i> , 1999 , 45, 421-9	9.4	288
717	A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. <i>Journal of Immunology</i> , 2002 , 168, 4772-80	5.3	277
716	Mechanisms of chemoresistance to alkylating agents in malignant glioma. <i>Clinical Cancer Research</i> , 2008 , 14, 2900-8	12.9	273
715	Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. <i>Cancer Research</i> , 2003 , 63, 7462-7	10.1	272
714	O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. <i>Journal of Neurochemistry</i> , 2006 , 96, 766-76	6	253
713	Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. <i>Journal of Neuroscience</i> , 2002 , 22, 6401-7	6.6	252
712	RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. <i>Cancer Research</i> , 2004 , 64, 7596-603	10.1	251
711	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. <i>Lancet Oncology, The</i> , 2015 , 16, e322-32	21.7	247
710	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). <i>Neuro-Oncology</i> , 2017 , 19, 162-174	1	244
709	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. <i>Acta Neuropathologica</i> , 2013 , 126, 443-51	14.3	239
708	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet, The</i> , 2017 , 390, 1645-1653	40	225
707	CD95/CD95 ligand interactions on epithelial cells in host defense to <i>Pseudomonas aeruginosa</i> . <i>Science</i> , 2000 , 290, 527-30	33.3	225
706	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , 2015 , 17, 1188-98	1	224

705	Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. <i>Stem Cells</i> , 2009 , 27, 909-19	5.8	224
704	MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. <i>Acta Neuropathologica</i> , 2012 , 124, 547-60	14.3	213
703	Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. <i>International Journal of Cancer</i> , 2011 , 129, 659-70	7.5	213
702	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. <i>Acta Neuropathologica</i> , 2013 , 126, 907-15	14.3	211
701	Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. <i>Acta Neuropathologica</i> , 2015 , 129, 679-93	14.3	208
700	Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3357-61	2.2	208
699	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 678-688	40	207
698	MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. <i>Clinical Cancer Research</i> , 2015 , 21, 2057-64	12.9	206
697	Corticosteroids compromise survival in glioblastoma. <i>Brain</i> , 2016 , 139, 1458-71	11.2	205
696	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 170-186	19.4	204
695	Predicting response to cancer chemotherapy: the role of p53. <i>Cell and Tissue Research</i> , 1998 , 292, 435-454	4.2	199
694	Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [F]FDG: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 540-557	8.8	198
693	cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. <i>Brain Pathology</i> , 2020 , 30, 844-856	6	196
692	Immunosuppressive mechanisms in glioblastoma. <i>Neuro-Oncology</i> , 2015 , 17 Suppl 7, vii9-vii14	1	195
691	Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. <i>Journal of Neuro-Oncology</i> , 2001 , 53, 177-85	4.8	195
690	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. <i>Acta Neuropathologica</i> , 2015 , 130, 407-17	14.3	194
689	Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. <i>European Journal of Immunology</i> , 1995 , 25, 2253-8	6.1	191
688	Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. <i>Microscopy Research and Technique</i> , 2001 , 52, 401-10	2.8	190

687	Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 265, 479-83	3.4	188
686	EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. <i>Cancer Cell</i> , 2013 , 24, 438-49	24.3	181
685	Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. <i>International Journal of Cancer</i> , 2012 , 131, 1342-50	7.5	180
684	Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. <i>Annals of Neurology</i> , 2003 , 54, 388-92	9.4	180
683	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020 , 22, 1073-1113	1	178
682	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. <i>Nature Medicine</i> , 2018 , 24, 1192-1203	50.5	174
681	ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. <i>International Journal of Oncology</i> , 2014 , 44, 1843-52	4.4	174
680	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. <i>Acta Neuropathologica</i> , 2020 , 139, 603-608	14.3	170
679	TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. <i>Brain</i> , 2006 , 129, 2416-25	11.2	170
678	Molecular targeted therapy of glioblastoma. <i>Cancer Treatment Reviews</i> , 2019 , 80, 101896	14.4	167
677	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , 2018 , 136, 153-166	14.3	162
676	Induction of nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal PC12 cells after stimulation with tumor necrosis factor-alpha/lipopolysaccharide. <i>Journal of Neurochemistry</i> , 1998 , 71, 88-94	6	161
675	Glioblastoma. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 134, 381-97	3	160
674	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. <i>Neurology</i> , 2013 , 81, 1515-22	6.5	160
673	Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invasive Leukocytes. <i>Cell</i> , 2020 , 181, 1626-1642.e20	56.2	154
672	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019 , 576, 112-120	50.4	151
671	Molecular neuro-oncology in clinical practice: a new horizon. <i>Lancet Oncology, The</i> , 2013 , 14, e370-9	21.7	149
670	Surgery for primary CNS lymphoma? Challenging a paradigm. <i>Neuro-Oncology</i> , 2012 , 14, 1481-4	1	149

669	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. <i>Acta Neuropathologica</i> , 2014 , 128, 561-71	14.3	148
668	Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. <i>Journal of Experimental Medicine</i> , 2013 , 210, 2803-11	16.6	147
667	Molecular markers in low-grade gliomas: predictive or prognostic?. <i>Clinical Cancer Research</i> , 2011 , 17, 4588-99	12.9	145
666	APO2 ligand: a novel lethal weapon against malignant glioma?. <i>FEBS Letters</i> , 1998 , 427, 124-8	3.8	145
665	Invasion patterns in brain metastases of solid cancers. <i>Neuro-Oncology</i> , 2013 , 15, 1664-72	1	143
664	A specific miRNA signature in the peripheral blood of glioblastoma patients. <i>Journal of Neurochemistry</i> , 2011 , 118, 449-57	6	141
663	European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. <i>Lancet Oncology</i> , 2017 , 18, e330-e340	21.7	138
662	Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. <i>Oncogene</i> , 2000 , 19, 4210-20	9.2	138
661	MICA/NKG2D-mediated immunogene therapy of experimental gliomas. <i>Cancer Research</i> , 2003 , 63, 8996-9006	10.6	137
660	Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4412-7	2.2	131
659	Therapeutic options in recurrent glioblastoma--An update. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 389-408	7	130
658	Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. <i>International Journal of Cancer</i> , 1998 , 79, 640-4	7.5	130
657	Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. <i>Neuro-Oncology</i> , 2016 , 18, 549-56	1	129
656	mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 409-14	11.5	126
655	Leptomeningeal metastasis: survival and prognostic factors in 155 patients. <i>Journal of the Neurological Sciences</i> , 2004 , 223, 167-78	3.2	126
654	New (alternative) temozolomide regimens for the treatment of glioma. <i>Neuro-Oncology</i> , 2009 , 11, 69-79	1	125
653	CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. <i>EMBO Journal</i> , 2011 , 30, 4309-22	13	123
652	Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3276-84	2.2	121

651	Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. <i>Clinical Cancer Research</i> , 2013 , 19, 5146-57	12.9	120
650	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. <i>Neuro-Oncology</i> , 2012 , 14 Suppl 4, iv100-8	1	120
649	Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 268, 607-11	3.4	120
648	Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. <i>Journal of Immunology</i> , 2008 , 180, 7338-48	5.3	119
647	Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?. <i>Clinical Cancer Research</i> , 2007 , 13, 6933-7	12.9	119
646	Fas/CD95/Apo-I activates the acidic sphingomyelinase via caspases. <i>Cell Death and Differentiation</i> , 1998 , 5, 29-37	12.7	118
645	NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. <i>Cancer Research</i> , 2018 , 78, 1031-1043	10.1	117
644	Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. <i>Current Pharmaceutical Design</i> , 2006 , 12, 341-9	3.3	113
643	Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. <i>Neurology</i> , 2015 , 84, 710-9	6.5	112
642	Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. <i>Journal of Neuro-Oncology</i> , 2010 , 96, 393-402	4.8	111
641	HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005 , 64, 523-8	3.1	110
640	Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. <i>Cell Death and Differentiation</i> , 1999 , 6, 370-6	12.7	109
639	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 731-9 ^{2.2}		108
638	Optimal management of elderly patients with glioblastoma. <i>Cancer Treatment Reviews</i> , 2013 , 39, 350-7	14.4	108
637	Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1257-61	2.2	108
636	Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. <i>Journal of Neurochemistry</i> , 2012 , 122, 444-55	6	107
635	Epilepsy meets cancer: when, why, and what to do about it?. <i>Lancet Oncology, The</i> , 2012 , 13, e375-82	21.7	107
634	Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. <i>Brain</i> , 2006 , 129, 2426-35	11.2	107

633	GDF-15 contributes to proliferation and immune escape of malignant gliomas. <i>Clinical Cancer Research</i> , 2010 , 16, 3851-9	12.9	105
632	Pathway inhibition: emerging molecular targets for treating glioblastoma. <i>Neuro-Oncology</i> , 2011 , 13, 566-79	1	104
631	Expression pattern of the water channel aquaporin-4 in human gliomas is associated with blood-brain barrier disturbance but not with patient survival. <i>Journal of Neuroscience Research</i> , 2007 , 85, 1336-46	4.4	103
630	Transforming growth factor-beta 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. <i>European Journal of Immunology</i> , 1994 , 24, 1293-300	6.1	103
629	PTEN methylation and expression in glioblastomas. <i>Acta Neuropathologica</i> , 2003 , 106, 479-85	14.3	102
628	Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. <i>Journal of Neurochemistry</i> , 2005 , 93, 992-9	6	102
627	Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. <i>Acta Neuropathologica</i> , 2018 , 136, 793-803	14.3	102
626	EANO guidelines for the diagnosis and treatment of ependymal tumors. <i>Neuro-Oncology</i> , 2018 , 20, 445-456		100
625	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. <i>Acta Neuropathologica</i> , 2018 , 136, 273-291	14.3	99
624	CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. <i>Oncogene</i> , 2001 , 20, 4128-37	9.2	98
623	PET imaging in patients with meningioma-report of the RANO/PET Group. <i>Neuro-Oncology</i> , 2017 , 19, 1576-1587	1	97
622	Molecular determinants of glioma cell migration and invasion. <i>Journal of Neurosurgery</i> , 2001 , 94, 978-84	3.2	97
621	PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. <i>Oncogene</i> , 1999 , 18, 3936-43	9.2	97
620	Molecular diagnostics of gliomas: the clinical perspective. <i>Acta Neuropathologica</i> , 2010 , 120, 585-92	14.3	96
619	Both the neuronal and inducible isoforms contribute to upregulation of retinal nitric oxide synthase activity by brain-derived neurotrophic factor. <i>Journal of Neuroscience</i> , 1999 , 19, 8517-27	6.6	96
618	Glucocorticoid treatment of primary CNS lymphoma. <i>Journal of Neuro-Oncology</i> , 1999 , 43, 237-9	4.8	96
617	Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. <i>PLoS ONE</i> , 2012 , 7, e33449	3.7	96
616	Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in -Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors. <i>Clinical Cancer Research</i> , 2017 , 23, 6846-6855	12.9	94

615	Evolutionary Trajectories of IDH Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. <i>Cancer Cell</i> , 2019 , 35, 692-704.e12	24.3	92
614	Bevacizumab and recurrent malignant gliomas: a European perspective. <i>Journal of Clinical Oncology</i> , 2010 , 28, e188-9; author reply e190-2	2.2	92
613	Costimulatory protein 4lgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. <i>Clinical Cancer Research</i> , 2012 , 18, 105-17	12.9	91
612	Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. <i>International Journal of Cancer</i> , 2014 , 135, 1822-31	7.5	89
611	Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. <i>Cell Death and Differentiation</i> , 1998 , 5, 847-57	12.7	89
610	Processing of immunosuppressive pro-TGF-beta 1,2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. <i>Journal of Immunology</i> , 2001 , 166, 7238-43	5.3	87
609	Cooperative interception of neuronal apoptosis by BCL-2 and BAG-1 expression: prevention of caspase activation and reduced production of reactive oxygen species. <i>Journal of Neurochemistry</i> , 1997 , 69, 2075-86	6	83
608	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017 , 13, 363-374	15	82
607	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. <i>Neuro-Oncology</i> , 2017 , 19, 1119-1126	1	82
606	Cilengitide: an RGD pentapeptide α and β integrin inhibitor in development for glioblastoma and other malignancies. <i>Future Oncology</i> , 2011 , 7, 339-54	3.6	82
605	Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone?. <i>Neurology</i> , 1997 , 48, 1704-9	6.5	81
604	Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins. <i>Glia</i> , 2003 , 42, 379-89	9	81
603	Rechallenge with temozolomide in patients with recurrent gliomas. <i>Journal of Neurology</i> , 2009 , 256, 734-41	5.5	80
602	Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2. <i>Journal of Neuroscience</i> , 2001 , 21, 3360-8	6.6	80
601	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. <i>Neuro-Oncology</i> , 2016 , 18, 1529-1537	1	80
600	A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. <i>Neuro-Oncology</i> , 2017 , 19, 614-624	1	79
599	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , 2019 , 21, 901-910	1	79
598	Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. <i>Cancer Cell</i> , 2018 , 34, 163-177.e7	24.3	79

597	BCL-2 promotes migration and invasiveness of human glioma cells. <i>FEBS Letters</i> , 1998 , 440, 419-24	3.8	79
596	MLTI-13. RESPONSE ASSESSMENT OF MELANOMA BRAIN METASTASES TREATED BY STEREOTACTIC RADIOTHERAPY OR IMMUNOTHERAPY OR BOTH: A COMPARISON OF RECIST 1.1, RANO AND iRANO CRITERIA. <i>Neuro-Oncology Advances</i> , 2019 , 1, i17-i17	0.9	78
595	ACTR-23. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: FIRST RESULTS FROM THE BRAIN TUMOR FUNDERS COLLABORATIVE CONSORTIUM. <i>Neuro-Oncology</i> , 2017 , 19, vi5-vi6	1	78
594	Integrin isoform expression in primary human tumors and brain metastases. <i>International Journal of Cancer</i> , 2013 , 133, 2362-71	7.5	78
593	42. IDENTIFICATION OF BRAIN METASTASIS VULNERABILITIES USING METPLATFORM. <i>Neuro-Oncology Advances</i> , 2020 , 2, ii8-ii8	0.9	78
592	HG-68 COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA. <i>Neuro-Oncology</i> , 2016 , 18, iii63.2-iii63	1	78
591	CSIG-06. DEPATUXIZUMAB MAFODOTIN (ABT-414)-INDUCED GLIOBLASTOMA CELL DEATH REQUIRES EGFR OVEREXPRESSION, BUT NOT PHOSPHORYLATION. <i>Neuro-Oncology</i> , 2019 , 21, vi45-vi45 ¹		78
590	EPID-10. VENOUS THROMBOEMBOLIC EVENTS IN GLIOBLASTOMA PATIENTS: AN EPIDEMIOLOGICAL VIEW. <i>Neuro-Oncology</i> , 2019 , 21, vi76-vi76	1	78
589	DDIS-04. INTERFERON- β SENSITIZES HUMAN GLIOBLASTOMA CELLS TO THE CYCLIN-DEPENDENT KINASE INHIBITOR, TG02. <i>Neuro-Oncology</i> , 2019 , 21, vi65-vi66	1	78
588	CBMT-12. FOCAD LOSS IMPACTS MICROTUBULE ASSEMBLY, G2/M PROGRESSION AND PATIENT SURVIVAL IN ASTROCYTIC GLIOMAS. <i>Neuro-Oncology</i> , 2019 , 21, vi35-vi35	1	78
587	IMMU-17. TARGETING GLIOBLASTOMA WITH DNAM-1-BASED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS. <i>Neuro-Oncology</i> , 2019 , 21, vi122-vi122	1	78
586	IMMU-08. THE ANTIGENIC LANDSCAPE OF GLIOBLASTOMA - REFINING THE TARGETS FOR IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2019 , 21, vi120-vi120	1	78
585	QOLP-04. CALCULATING THE NET CLINICAL BENEFIT IN BRAIN TUMOR TRIALS BY COMBINING SURVIVAL AND HEALTH-RELATED QUALITY OF LIFE DATA USING TWO METHODS: QUALITY ADJUSTED SURVIVAL EFFECT SIZES AND JOINT MODELLING. <i>Neuro-Oncology</i> , 2019 , 21, vi198-vi198	1	78
584	ACTR-53. STEAM / EORTC 1608: STUDY OF TG02 IN ELDERLY NEWLY DIAGNOSED OR ADULT RELAPSED PATIENTS WITH ANAPLASTIC ASTROCYTOMA OR GLIOBLASTOMA - A PHASE 1B STUDY. <i>Neuro-Oncology</i> , 2018 , 20, vi23-vi24	1	78
583	RBTT-08. EORTC 1709/CCTG CE.8: A PHASE III TRIAL OF MARIZOMIB IN COMBINATION WITH STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY VERSUS STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018 , 20, vi235-vi236	1	78
582	PATH-51. DNA COPY NUMBER PROFILING ACROSS GLIOBLASTOMA POPULATIONS HAS IMPLICATIONS FOR CLINICAL TRIAL DESIGN. <i>Neuro-Oncology</i> , 2018 , 20, vi169-vi170	1	78
581	QOLP-29. SYMPTOM CLUSTERS IN NEWLY DIAGNOSED GLIOMA PATIENTS: WHICH CLUSTERS ARE ASSOCIATED WITH FUNCTIONING AND GLOBAL HEALTH STATUS?. <i>Neuro-Oncology</i> , 2018 , 20, vi221-vi221 ¹		78
580	ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL. <i>Neuro-Oncology</i> , 2018 , 20, vi22-vi22	1	78

579	CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018 , 20, vi48-vi49	1	78
578	CSIG-26. MOLECULAR DETERMINANTS OF SENSITIVITY TO PI3K/AKT/mTOR PATHWAY INHIBITION IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018 , 20, vi48-vi48	1	78
577	ACTR-61. LONG-TERM ANALYSES OF THE NOA-08 RANDOMIZED PHASE III TRIAL. <i>Neuro-Oncology</i> , 2018 , 20, vi25-vi25	1	78
576	ACTR-16. PERIPHERAL BLOOD CD4+ MONONUCLEAR CELL FRACTIONS ARE ASSOCIATED WITH OVERALL SURVIVAL AT FIRST RECURRENCE OF IDH-WILDTYPE GLIOBLASTOMA AFTER STANDARD CHEMORADIO THERAPY: SECONDARY ANALYSES OF THE PHASE II DIRECTOR TRIAL. <i>Neuro-Oncology</i> , 2018 , 20, vi14-vi14	1	78
575	CMET-26. PERIOPERATIVE IMAGING OF BRAIN METASTASES: A EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY (EANO) YOUNGSTERS SURVEY. <i>Neuro-Oncology</i> , 2018 , 20, vi59-vi59	1	78
574	MNGI-14. LOSS OF HISTONE H3K27me3 IDENTIFIES A SUBSET OF MENINGIOMAS WITH INCREASED RISK OF RECURRENCE. <i>Neuro-Oncology</i> , 2018 , 20, vi151-vi151	1	78
573	MNGI-05. DEVELOPMENT AND VALIDATION OF A DNA METHYLOME-BASED PREDICTOR OF MENINGIOMA RECURRENCE AND MENINGIOMA RECURRENCE SCORE. <i>Neuro-Oncology</i> , 2018 , 20, vi148-vi149	1	78
572	QOLP-27. USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE IN GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2018 , 20, vi220-vi220	1	78
571	SURG-10. The evolving role of neurosurgery for central nervous system metastases in the era of personalized medicine. <i>Neuro-Oncology Advances</i> , 2021 , 3, iii25-iii25	0.9	78
570	BSCI-02. METPlatform identifies brain metastasis vulnerabilities and predicts patient response to therapy. <i>Neuro-Oncology Advances</i> , 2021 , 3, iii1-iii1	0.9	78
569	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O-Methylguanine-DNA Methyltransferase Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017 , 35, 343-351	2.2	77
568	Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. <i>Cancer Research</i> , 2007 , 67, 3540-4	10.1	77
567	Phase II Study of Radiotherapy and Temozolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). <i>Clinical Cancer Research</i> , 2016 , 22, 4797-4806	12.9	77
566	Integrin control of the transforming growth factor- β pathway in glioblastoma. <i>Brain</i> , 2013 , 136, 564-76	11.2	76
565	Apoptosis in gliomas: molecular mechanisms and therapeutic implications. <i>Journal of Neuro-Oncology</i> , 2004 , 70, 245-54	4.8	74
564	N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta release and reduces migration and invasiveness of human malignant glioma cells. <i>International Journal of Cancer</i> , 2001 , 93, 53-61	7.5	74
563	Assessment and prognostic significance of the epidermal growth factor receptor VIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. <i>International Journal of Cancer</i> , 2014 , 134, 2437-47	7.5	73
562	Targeting integrins in malignant glioma. <i>Targeted Oncology</i> , 2010 , 5, 175-81	5	73

561	Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells. <i>Brain</i> , 2005 , 128, 2200-11	11.2	73
560	Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. <i>Cancer Research</i> , 2002 , 62, 1915-9	10.1	73
559	Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. <i>Neurology</i> , 2015 , 84, 1242-8	6.5	72
558	Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. <i>Neuro-Oncology</i> , 2007 , 9, 259-70	1	72
557	PET imaging in patients with brain metastasis-report of the RANO/PET group. <i>Neuro-Oncology</i> , 2019 , 21, 585-595	1	72
556	2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. <i>International Journal of Cancer</i> , 2012 , 131, 766-8	7.5	70
555	Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. <i>Cancer Gene Therapy</i> , 2004 , 11, 721-32	5.4	69
554	Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. <i>Acta Neuropathologica</i> , 2012 , 123, 841-52	14.3	68
553	Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. <i>Neuro-Oncology</i> , 2009 , 11, 747-56	1	68
552	Transforming growth factor- β pathway activity in glioblastoma. <i>Oncotarget</i> , 2015 , 6, 5963-77	3.3	68
551	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2019 , 21, 571-584	1	67
550	Synergistic antiglioma activity of radiotherapy and enzastaurin. <i>Annals of Neurology</i> , 2007 , 61, 153-61	9.4	67
549	BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. <i>Journal of the Neurological Sciences</i> , 1998 , 155, 68-75	3.2	67
548	Epidermal growth factor receptor: a re-emerging target in glioblastoma. <i>Current Opinion in Neurology</i> , 2012 , 25, 774-9	7.1	66
547	Steroids in neurooncology: actions, indications, side-effects. <i>Current Opinion in Neurology</i> , 2010 , 23, 597-602	6.0	66
546	Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 1998 , 43, 116-20	9.4	66
545	Gliomatosis cerebri: molecular pathology and clinical course. <i>Annals of Neurology</i> , 2002 , 52, 390-9	9.4	66
544	MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. <i>Oncotarget</i> , 2014 , 5, 7651-62	3.3	66

543	EANO guideline on the diagnosis and treatment of vestibular schwannoma. <i>Neuro-Oncology</i> , 2020 , 22, 31-45	1	66
542	Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. <i>Acta Neuropathologica Communications</i> , 2017 , 5, 39	7.3	65
541	Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. <i>Genome Biology</i> , 2015 , 16, 16	18.3	65
540	Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. <i>Neuro-Oncology</i> , 2017 , 19, 12-21	1	65
539	Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. <i>Neuro-Oncology</i> , 2013 , 15, 1017-26	1	65
538	Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death. <i>Cancer Research</i> , 2004 , 64, 1575-8	10.1	64
537	Modulation of growth and radiochemosensitivity of human malignant glioma cells by acidosis. <i>Cancer</i> , 2002 , 95, 1113-9	6.4	64
536	Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone. <i>International Journal of Cancer</i> , 1997 , 73, 707-14	7.5	63
535	A novel tool to analyze MRI recurrence patterns in glioblastoma. <i>Neuro-Oncology</i> , 2008 , 10, 1019-24	1	63
534	Bevacizumab does not increase the risk of remote relapse in malignant glioma. <i>Annals of Neurology</i> , 2011 , 69, 586-92	9.4	62
533	CD95 ligand: lethal weapon against malignant glioma?. <i>Brain Pathology</i> , 1998 , 8, 285-93	6	62
532	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. <i>Neuro-Oncology</i> , 2020 , 22, 684-693	1	62
531	Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. <i>Acta Neuropathologica</i> , 2018 , 135, 955-963	14.3	61
530	Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation?. <i>Oncogene</i> , 1998 , 17, 1567-75	9.2	61
529	Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. <i>International Journal of Cancer</i> , 2015 , 136, 2132-45	7.5	60
528	Gliomatosis cerebri: no evidence for a separate brain tumor entity. <i>Acta Neuropathologica</i> , 2016 , 131, 309-319	14.3	59
527	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. <i>Neuro-Oncology</i> , 2014 , 16, 1630-8	12.9	59
526	Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. <i>Clinical Cancer Research</i> , 2019 , 25, 1809-1816	12.9	59

525	Profiling walking dysfunction in multiple sclerosis: characterisation, classification and progression over time. <i>Scientific Reports</i> , 2018 , 8, 4984	4.9	58
524	Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. <i>Acta Neuropathologica</i> , 2011 , 122, 353-65	14.3	58
523	Individualized targeted therapy for glioblastoma: fact or fiction?. <i>Cancer Journal (Sudbury, Mass)</i> , 2012 , 18, 40-4	2.2	57
522	The network of immunosuppressive pathways in glioblastoma. <i>Biochemical Pharmacology</i> , 2017 , 130, 1-9	6	56
521	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2019 , 21, 26-36	1	54
520	Biological activity of tumor-treating fields in preclinical glioma models. <i>Cell Death and Disease</i> , 2017 , 8, e2753	9.8	53
519	Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 328, 125-9	3.4	53
518	Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. <i>Neuro-Oncology</i> , 2018 , 20, 279-288	1	52
517	Differential regulation of TGF- β -induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma. <i>Neuro-Oncology</i> , 2015 , 17, 254-65	1	52
516	Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. <i>Biochemical and Biophysical Research Communications</i> , 2004 , 321, 524-30	3.4	52
515	Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. <i>Cancer</i> , 2016 , 122, 2206-15	6.4	52
514	⁶⁸ Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?. <i>Neuro-Oncology</i> , 2016 , 18, 1021-7	1	51
513	Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity. <i>Journal of Neurochemistry</i> , 2004 , 91, 1067-74	6	51
512	The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. <i>Neuro-Oncology</i> , 2019 , 21, 648-658	1	50
511	Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. <i>Neuro-Oncology</i> , 2014 , 16, 584-8	1	50
510	Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing. <i>Cell Death and Differentiation</i> , 1998 , 5, 894-900	12.7	50
509	Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 259, 600-5	3.4	50
508	Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to ⁶⁸ Ga-DOTATATE/-TOC uptake. <i>Neuro-Oncology</i> , 2016 , 18, 1538-1547	1	50

507	Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1170-1179	21.7	49
506	Targeting apoptosis pathways in glioblastoma. <i>Cancer Letters</i> , 2013 , 332, 335-45	9.9	49
505	NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. <i>Annals of Neurology</i> , 2011 , 70, 445-53	9.4	49
504	Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. <i>Oncogene</i> , 2001 , 20, 4757-67	9.2	49
503	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. <i>Oncotarget</i> , 2016 , 7, 15018-32	3.3	49
502	PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?. <i>Clinical Cancer Research</i> , 2020 , 26, 5287-5296	12.9	48
501	Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. <i>Neuro-Oncology</i> , 2016 , 18, 1242-52	1	48
500	Pirfenidone inhibits TGF-beta expression in malignant glioma cells. <i>Biochemical and Biophysical Research Communications</i> , 2007 , 354, 542-7	3.4	47
499	Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long?. <i>Oncology Research and Treatment</i> , 2005 , 28, 391-6	2.8	47
498	FasL (CD95L/APO-1L) resistance of neurons mediated by phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent expression of lifeguard/neuronal membrane protein 35. <i>Journal of Neuroscience</i> , 2005 , 25, 6765-74	6.6	47
497	MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. <i>Oncotarget</i> , 2016 , 7, 12937-50	3.3	47
496	Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 744-51	1	46
495	Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. <i>Journal of Neuroimmunology</i> , 2007 , 189, 50-8	3.5	46
494	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. <i>Neuro-Oncology</i> , 2020 , 22, 757-772	1	45
493	Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. <i>Journal of Neuro-Oncology</i> , 2014 , 117, 141-5	4.8	45
492	Radiochemotherapy of malignant glioma in adults. Clinical experiences. <i>Strahlentherapie Und Onkologie</i> , 2003 , 179, 219-32	4.3	45
491	BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells. <i>Journal of Neuro-Oncology</i> , 2002 , 56, 43-9	4.8	44
490	Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells. <i>Oncogene</i> , 1999 , 18, 5044-53	9.2	44

489	Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. <i>European Journal of Pharmacology</i> , 1999 , 365, 301-8	5.3	44
488	High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. <i>Molecular Oncology</i> , 2019 , 13, 2305-2328	7.9	43
487	Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. <i>Lancet Oncology, The</i> , 2012 , 13, e196-204	21.7	43
486	Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. <i>Current Neurology and Neuroscience Reports</i> , 2011 , 11, 305-12	6.6	43
485	Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). <i>Stem Cells and Development</i> , 2010 , 19, 657-68	4.4	43
484	How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4235-6; author reply 4236	2.2	43
483	Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatment. <i>Cancer</i> , 2001 , 91, 130-5	6.4	43
482	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. <i>Neuro-Oncology</i> , 2020 , 22, 17-30	1	43
481	Glioblastoma quo vadis: Will migration and invasiveness reemerge as therapeutic targets?. <i>Cancer Treatment Reviews</i> , 2018 , 68, 145-154	14.4	43
480	Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies. <i>Neuro-Oncology</i> , 2014 , 16 Suppl 8, viii14-9	1	42
479	Modulation of cerebral endothelial cell function by TGF- β in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition. <i>Oncotarget</i> , 2015 , 6, 22480-95	3.3	42
478	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. <i>Neuro-Oncology</i> , 2016 , 18, 401-7	1	41
477	Modulation of TGF-beta activity by latent TGF-beta-binding protein 1 in human malignant glioma cells. <i>International Journal of Cancer</i> , 2009 , 125, 530-40	7.5	41
476	How did lomustine become standard of care in recurrent glioblastoma?. <i>Cancer Treatment Reviews</i> , 2020 , 87, 102029	14.4	40
475	Interferon- γ induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 948-61	6.1	40
474	Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. <i>Acta Neurochirurgica</i> , 2012 , 154, 229-35; discussion 235	3	40
473	Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 77, 670-6	4	40
472	How we treat glioblastoma. <i>ESMO Open</i> , 2019 , 4, e000520	6	39

471	A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. <i>Neuro-Oncology</i> , 2014 , 16, 382-91	1	39
470	Interferon-alpha enhances CD95L-induced apoptosis of human malignant glioma cells. <i>Journal of Neuroimmunology</i> , 1998 , 87, 121-9	3.5	39
469	Novel diagnostic and therapeutic approaches to malignant glioma. <i>Swiss Medical Weekly</i> , 2011 , 141, w133210	13.10	39
468	Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 1815-1821	4.9	38
467	Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe. <i>Journal of Neuro-Oncology</i> , 2017 , 133, 419-427	4.8	38
466	Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. <i>Neuro-Oncology</i> , 2020 , 22, 1262-1275	1	38
465	Immunological challenges for peptide-based immunotherapy in glioblastoma. <i>Cancer Treatment Reviews</i> , 2014 , 40, 248-58	14.4	38
464	Biological Role and Therapeutic Targeting of TGF- β in Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1177-1186	6.1	37
463	Predicting outcome of epilepsy after meningioma resection. <i>Neuro-Oncology</i> , 2016 , 18, 1002-10	1	37
462	APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. <i>Neuro-Oncology</i> , 2011 , 13, 155-64	1	37
461	P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells. <i>Brain Pathology</i> , 2003 , 13, 482-94	6	37
460	How we treat patients with leptomeningeal metastases. <i>ESMO Open</i> , 2019 , 4, e000507	6	37
459	NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma. <i>Clinical Cancer Research</i> , 2018 , 24, 882-895	12.9	37
458	Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). <i>Neuro-Oncology</i> , 2018 , 20, 400-410	1	36
457	cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. <i>Brain Pathology</i> , 2017 , 27, 851-852	6	36
456	Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. <i>Neuro-Oncology</i> , 2015 , 17, 1016-21	1	36
455	Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. <i>Glia</i> , 2011 , 59, 1200-4	9	36
454	ACNU-based chemotherapy for recurrent glioma in the temozolomide era. <i>Journal of Neuro-Oncology</i> , 2009 , 92, 45-8	4.8	36

453	Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. <i>Brain</i> , 2009 , 132, 1509-22	11.2	36
452	Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. <i>Neurological Research</i> , 1997 , 19, 456-470	2.7	36
451	Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release. <i>Oncogene</i> , 2000 , 19, 2338-45	9.2	36
450	Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes. <i>Journal of Controlled Release</i> , 2019 , 295, 130-139	11.7	36
449	Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. <i>Neurology</i> , 2017 , 88, 1422-1430	6.5	35
448	Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. <i>Neuro-Oncology</i> , 2018 , 20, 367-379	1	35
447	Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015 , 17, 1007-15 ¹		34
446	Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. <i>Acta Oncologica</i> , 2011 , 50, 630-5	3.2	34
445	New aspects of immunotherapy of leptomeningeal metastasis. <i>Journal of Neuro-Oncology</i> , 1998 , 38, 233-9	4.8	34
444	BCL-2-induced glioma cell invasiveness depends on furin-like proteases. <i>Journal of Neurochemistry</i> , 2004 , 91, 1275-83	6	34
443	EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2001-2001	2.2	34
442	HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. <i>Journal of Neuroimmunology</i> , 2012 , 250, 27-34	3.5	33
441	The role of integrins in glioma biology and anti-glioma therapies. <i>Current Pharmaceutical Design</i> , 2011 , 17, 2402-10	3.3	33
440	Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo. <i>International Journal of Cancer</i> , 2006 , 118, 1728-35	7.5	33
439	Modulation of MDR/MRP by wild-type and mutant p53. <i>Journal of Clinical Investigation</i> , 2001 , 107, 643-615,9		33
438	Neutrophils Obstructing Brain Capillaries Are a Major Cause of No-Reflow in Ischemic Stroke. <i>Cell Reports</i> , 2020 , 33, 108260	10.6	33
437	Corticosteroid use in neuro-oncology: an update. <i>Neuro-Oncology Practice</i> , 2015 , 2, 6-12	2.2	32
436	DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. <i>Neuro-Oncology</i> , 2018 , 20, 1616-1624	1	32

435	Tumor-associated edema in brain cancer patients: pathogenesis and management. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 1319-25	3.5	32
434	Adenoviral natural born killer gene therapy for malignant glioma. <i>Human Gene Therapy</i> , 2003 , 14, 1235-468	4.8	32
433	EANO guideline on the diagnosis and management of meningiomas. <i>Neuro-Oncology</i> , 2021 , 23, 1821-1834	3.4	32
432	Efficacy of Surgery and Further Treatment of Progressive Glioblastoma. <i>World Neurosurgery</i> , 2015 , 84, 301-7	2.1	31
431	Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1463-1475	5	31
430	Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. <i>Journal of the National Cancer Institute</i> , 2017 , 109, 1-4	9.7	31
429	CD95-Dependent T-Cell Killing by Glioma Cells Expressing CD95 Ligand: More on Tumor Immune Escape, the CD95 Counterattack, and the Immune Privilege of the Brain. <i>Cellular Physiology and Biochemistry</i> , 1997 , 7, 282-288	3.9	31
428	Lipoxygenase inhibitors block CD95 ligand-mediated apoptosis of human malignant glioma cells. <i>FEBS Letters</i> , 1997 , 409, 17-23	3.8	31
427	Control of glioma cell migration and invasiveness by GDF-15. <i>Oncotarget</i> , 2016 , 7, 7732-46	3.3	31
426	EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. <i>Lancet Oncology, The</i> , 2019 , 20, e715-e728	21.7	31
425	CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. <i>Brain Pathology</i> , 2002 , 12, 12-20	6	30
424	Thymosin β 4 gene silencing decreases stemness and invasiveness in glioblastoma. <i>Brain</i> , 2014 , 137, 433-481	48.2	29
423	Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?. <i>Journal of Neurochemistry</i> , 2014 , 131, 251-64	6	29
422	Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study. <i>Cancer</i> , 2001 , 91, 423-7	6.4	29
421	TGF-beta-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells. <i>European Journal of Immunology</i> , 1999 , 29, 1032-40	6.1	29
420	T cell apoptosis induced by interleukin-2 deprivation or transforming growth factor-beta 2: modulation by the phosphatase inhibitors okadaic acid and calyculin A. <i>Experimental Cell Research</i> , 1995 , 221, 395-403	4.2	29
419	ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRVIII-EXPRESSING GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2016 , 18, vi17-vi18	1	29
418	Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. <i>Neuro-Oncology</i> , 2017 , 19, 1338-1349	1	28

417	Iterative analysis of cerebrovascular reactivity dynamic response by temporal decomposition. <i>Brain and Behavior</i> , 2017 , 7, e00705	3.4	28
416	Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-beta, dexamethasone, and p53 gene transfer. <i>Oncogene</i> , 1998 , 17, 2323-32	9.2	28
415	Bag-1 and Bcl-2 gene transfer in malignant glioma: modulation of cell cycle regulation and apoptosis. <i>Brain Pathology</i> , 2000 , 10, 223-34	6	28
414	Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2000-2000	2.2	28
413	Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. <i>Acta Neuropathologica</i> , 2019 , 138, 295-308	14.3	27
412	Lymphatic outflow of cerebrospinal fluid is reduced in glioma. <i>Scientific Reports</i> , 2019 , 9, 14815	4.9	27
411	End-of-life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey. <i>Neuro-Oncology</i> , 2013 , 15, 1251-6	1	27
410	Chemosensitivity of human malignant glioma: modulation by p53 gene transfer. <i>Journal of Neuro-Oncology</i> , 1998 , 39, 19-32	4.8	27
409	Temozolomide: a milestone in the pharmacotherapy of brain tumors. <i>Future Oncology</i> , 2005 , 1, 747-54	3.6	27
408	Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells. <i>Acta Neuropathologica</i> , 2001 , 101, 217-24	14.3	27
407	p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis. <i>Cellular Physiology and Biochemistry</i> , 1999 , 9, 29-37	3.9	27
406	Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis. <i>Neurology</i> , 2017 , 88, 832-841	6.5	26
405	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , 2020 , 140, 409-413	14.3	26
404	Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. <i>Neuro-Oncology</i> , 2019 , 21, 1587-1594	15.94	26
403	Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma? 2015 , 34, 313-21		26
402	Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. <i>European Journal of Cancer</i> , 2015 , 51, 382-90	7.5	26
401	Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. <i>Journal of Neurosurgery</i> , 2010 , 113, 280-5	3.2	26
400	Expression and putative functions of GDF-15, a member of the TGF-beta superfamily, in human glioma and glioblastoma cell lines. <i>Cancer Letters</i> , 2008 , 270, 30-9	9.9	26

399	Involvement of protein kinase Cdelta and extracellular signal-regulated kinase-2 in the suppression of microglial inducible nitric oxide synthase expression by N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast). <i>Biochemical Pharmacology</i> , 2003 , 66, 1263-70	6	26
398	Potential of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2. <i>Biochemical Pharmacology</i> , 1998 , 55, 349-59	6	26
397	A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS2079-TPS2079	2.2	26
396	Immunocytokines are a promising immunotherapeutic approach against glioblastoma. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	26
395	HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy 2021 , 9,		26
394	Immunological effects of chemotherapy and radiotherapy against brain tumors. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 1087-94	3.5	26
393	Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2018 , 20, 897-906	1	26
392	Malignant optic glioma - the spectrum of disease in a case series. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2015 , 253, 1187-94	3.8	25
391	Barriers to accrual and enrollment in brain tumor trials. <i>Neuro-Oncology</i> , 2019 , 21, 1100-1117	1	25
390	Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. <i>European Journal of Cancer</i> , 2017 , 87, 189-198	7.5	25
389	Will integrin inhibitors have proangiogenic effects in the clinic?. <i>Nature Medicine</i> , 2009 , 15, 726; author reply 727	50.5	25
388	Death receptor-mediated apoptosis in human malignant glioma cells: modulation by the CD40/CD40L system. <i>Journal of Neuroimmunology</i> , 2005 , 162, 28-42	3.5	25
387	Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. <i>Neuro-Oncology</i> , 2020 , 22, 524-538	1	25
386	The Role of Molecular Diagnostics in the Management of Patients with Gliomas. <i>Current Treatment Options in Oncology</i> , 2016 , 17, 51	5.4	25
385	Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?. <i>Journal of Neuro-Oncology</i> , 2018 , 138, 163-171	4.8	24
384	Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. <i>Journal of Neuro-Oncology</i> , 2016 , 129, 165-71	4.8	24
383	Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL. <i>Journal of Neurochemistry</i> , 2008 , 106, 2436-48	6	24
382	Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study. <i>Journal of Neuro-Oncology</i> , 2002 , 59, 151-5	4.8	24

381	Caspase-dependent chemotherapy-induced death of glioma cells requires mitochondrial cytochrome c release. <i>Biochemical and Biophysical Research Communications</i> , 2001 , 281, 322-7	3.4	24
380	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA2009-LBA2009	2.2	24
379	YAP1-fusions in pediatric NF2-wildtype meningioma. <i>Acta Neuropathologica</i> , 2020 , 139, 215-218	14.3	24
378	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncology, The</i> , 2021 , 22, 813-823	21.7	24
377	Management of low-grade glioma: a systematic review and meta-analysis. <i>Neuro-Oncology Practice</i> , 2019 , 6, 249-258	2.2	24
376	Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. <i>Lancet Oncology, The</i> , 2018 , 19, e173-e180	21.7	23
375	Interleukin-33 in human gliomas: Expression and prognostic significance. <i>Oncology Letters</i> , 2016 , 12, 445-452	2.6	23
374	Negative control of the HGF/c-MET pathway by TGF- β a new look at the regulation of stemness in glioblastoma. <i>Cell Death and Disease</i> , 2017 , 8, 3210	9.8	23
373	A tissue-based draft map of the murine MHC class I immunopeptidome. <i>Scientific Data</i> , 2018 , 5, 180157	8.2	23
372	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. <i>Neuro-Oncology</i> , 2021 , 23, 881-893	1	23
371	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. <i>Neuro-Oncology</i> , 2020 , 22, 1162-1172	1	22
370	Limited role for transforming growth factor- β pathway activation-mediated escape from VEGF inhibition in murine glioma models. <i>Neuro-Oncology</i> , 2016 , 18, 1610-1621	1	22
369	Targeting the Potassium Channel Kv1.3 Kills Glioblastoma Cells. <i>NeuroSignals</i> , 2017 , 25, 26-38	1.9	22
368	Immunotherapy for glioblastoma: concepts and challenges. <i>Current Opinion in Neurology</i> , 2015 , 28, 639-461	4.1	22
367	Tumor cell dissemination triggers an intrathecal immune response in neoplastic meningitis. <i>Cancer</i> , 1992 , 69, 1475-80	6.4	22
366	Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2015-2015	2.2	22
365	Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab. <i>Neuro-Oncology</i> , 2017 , 19, 454-456	1	22
364	Therapeutic Targeting of TGF β Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas. <i>Clinical Cancer Research</i> , 2019 , 25, 7189-7201	12.9	22

363	Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization. <i>EMBO Molecular Medicine</i> , 2019 , 11,	12	21
362	Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. <i>Cancer Letters</i> , 2020 , 480, 24-28	9.9	21
361	Shaping the glioma immune microenvironment through tryptophan metabolism. <i>CNS Oncology</i> , 2012 , 1, 99-106	4	21
360	Regeneration and tolerance factor: a novel mediator of glioblastoma-associated immunosuppression. <i>Cancer Research</i> , 2006 , 66, 3852-8	10.1	21
359	Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1259-70	4	21
358	TGF- β induces oncofetal fibronectin that, in turn, modulates TGF- β superfamily signaling in endothelial cells. <i>Journal of Cell Science</i> , 2018 , 131,	5.3	20
357	Clinical implications of molecular neuropathology and biomarkers for malignant glioma. <i>Current Neurology and Neuroscience Reports</i> , 2012 , 12, 302-7	6.6	20
356	Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. <i>European Neurology</i> , 2013 , 69, 95-101	2.1	20
355	Geriatric neuro-oncology: from mythology to biology. <i>Current Opinion in Neurology</i> , 2011 , 24, 599-604	7.1	20
354	Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. <i>Future Oncology</i> , 2010 , 6, 1407-14	3.6	20
353	Is there a role for benzodiazepines in the management of lumbar disc prolapse with acute sciatica?. <i>Pain</i> , 2010 , 149, 470-475	8	20
352	Inhibition of experimental rat glioma growth by decorin gene transfer is associated with decreased microglial infiltration. <i>Journal of Neuroimmunology</i> , 1999 , 99, 13-8	3.5	20
351	Management of neoplastic meningitis. <i>Chinese Clinical Oncology</i> , 2015 , 4, 26	2.3	20
350	Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. <i>International Journal of Cancer</i> , 2020 , 146, 803-809	7.5	20
349	Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. <i>Lancet Oncology</i> , 2020 , 21, e97-e103	21.7	19
348	Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. <i>Neuro-Oncology</i> , 2019 , 21, 1447-1457	1	19
347	3-Nitropropionic acid-induced ischemia tolerance in the rat brain is mediated by reduced metabolic activity and cerebral blood flow. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014 , 34, 1522-30	7.3	19
346	Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients. <i>Journal of Neuro-Oncology</i> , 2014 , 118, 321-328	4.8	19

345	Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 605-17	5.9	19
344	Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand. <i>Cellular Physiology and Biochemistry</i> , 2007 , 20, 23-34	3.9	19
343	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. <i>Acta Neuropathologica Communications</i> , 2019 , 7, 163	7.3	18
342	The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. <i>Acta Neuropathologica</i> , 2018 , 135, 923-938	14.3	18
341	Copy number profiling across glioblastoma populations has implications for clinical trial design. <i>Neuro-Oncology</i> , 2018 , 20, 1368-1373	1	18
340	Pathogenesis and management of primary CNS lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 623-33	3.5	18
339	Ceramide metabolism determines glioma cell resistance to chemotherapy. <i>Journal of Cellular Physiology</i> , 2009 , 221, 688-95	7	18
338	VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells. <i>Brain</i> , 2008 , 131, 2579-95	11.2	18
337	N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-gamma (IFN-gamma). <i>British Journal of Pharmacology</i> , 2001 , 134, 1279-84	8.6	18
336	Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status. <i>Experimental Cell Research</i> , 1999 , 253, 432-9	4.2	18
335	Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. <i>JCI Insight</i> , 2019 , 4,	9.9	18
334	Direct contact with perivascular tumor cells enhances integrin $\alpha 5 \beta 1$ signaling and migration of endothelial cells. <i>Oncotarget</i> , 2016 , 7, 43852-43867	3.3	18
333	CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. <i>Neuro-Oncology</i> , 2021 , 23, 457-467	1	18
332	Hyper-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma. <i>Blood</i> , 2018 , 132, 2744-2753	2.2	18
331	Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild-type glioblastoma. <i>Genes Chromosomes and Cancer</i> , 2014 , 53, 589-605	5	17
330	Neuro-oncology in 2013: improving outcome in newly diagnosed malignant glioma. <i>Nature Reviews Neurology</i> , 2014 , 10, 68-70	15	17
329	SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo. <i>Clinical Cancer Research</i> , 2009 , 15, 6609-18	12.9	17
328	Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. <i>Neuro-Oncology</i> , 2021 , 23, 1100-1112	1	17

327	Proteasome inhibition for the treatment of glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 1133-1141	5.9	17
326	Evidence-based recommendations on categories for extent of resection in diffuse glioma. <i>European Journal of Cancer</i> , 2021 , 149, 23-33	7.5	17
325	Chemotherapy for intracranial ependymoma in adults. <i>BMC Cancer</i> , 2016 , 16, 287	4.8	17
324	Diffuse gliomas exhibit whole brain impaired cerebrovascular reactivity. <i>Magnetic Resonance Imaging</i> , 2018 , 45, 78-83	3.3	16
323	Altered intraoperative cerebrovascular reactivity in brain areas of high-grade glioma recurrence. <i>Magnetic Resonance Imaging</i> , 2016 , 34, 803-808	3.3	16
322	Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. <i>Current Treatment Options in Oncology</i> , 2013 , 14, 505-13	5.4	16
321	Anticoagulation for radiation-induced neurotoxicity revisited. <i>Journal of Neuro-Oncology</i> , 2008 , 90, 357-628	4.2	16
320	Apoptosis in gliomas, and its role in their current and future treatment. <i>Frontiers in Bioscience - Landmark</i> , 2002 , 7, e339-53	2.8	16
319	A prospective trial of mechanical physiotherapy for lumbar disk prolapse. <i>Journal of Neurology</i> , 2003 , 250, 746-9	5.5	16
318	Maturation-dependent modulation of apoptosis in cultured cerebellar granule neurons by cytokines and neurotrophins. <i>European Journal of Neuroscience</i> , 1996 , 8, 1994-2005	3.5	16
317	Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score. <i>Neuro-Oncology</i> , 2017 , 19, 1255-1262	1	15
316	Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. <i>Neuro-Oncology</i> , 2020 , 22, 1568-1579	1	15
315	Transcriptional control of O ⁶ -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma. <i>Journal of Neurochemistry</i> , 2018 , 144, 780-790	6	15
314	Treatment of primary CNS lymphoma. <i>Current Treatment Options in Neurology</i> , 2014 , 16, 277	4.4	15
313	Letter to the Editor: "The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline" [J Neurooncol 2014; 118:435-460]. <i>Journal of Neuro-Oncology</i> , 2014 , 120, 665-6	4.8	15
312	Regulation of pulmonary <i>Pseudomonas aeruginosa</i> infection by the transcriptional repressor Gfi1. <i>Cellular Microbiology</i> , 2006 , 8, 1096-105	3.9	15
311	Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo. <i>International Journal of Cancer</i> , 2005 , 117, 1060-4	7.5	15
310	Diva/Boo is a negative regulator of cell death in human glioma cells. <i>FEBS Letters</i> , 2001 , 505, 23-6	3.8	15

309	Prognostic relevance of miRNA-155 methylation in anaplastic glioma. <i>Oncotarget</i> , 2016 , 7, 82028-82045	3.3	15
308	Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition. <i>International Journal of Cancer</i> , 2019 , 145, 242-253	7.5	15
307	MiR-16-5p is frequently down-regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy. <i>Neuropathology and Applied Neurobiology</i> , 2019 , 45, 441-458	5.2	15
306	Glioma gene therapy with soluble transforming growth factor-beta receptors II and III. <i>International Journal of Oncology</i> , 2008 , 33, 759-65	1	15
305	Cutting Edge: ERK1 Mediates the Autocrine Positive Feedback Loop of TGF- β and Furin in Glioma-Initiating Cells. <i>Journal of Immunology</i> , 2017 , 198, 4569-4574	5.3	14
304	Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models. <i>Journal of Neurochemistry</i> , 2017 , 140, 170-182	6	14
303	Diagnostic value of F-fluorodesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. <i>European Journal of Cancer</i> , 2018 , 96, 64-72	7.5	14
302	How stemlike are sphere cultures from long-term cancer cell lines? Lessons from mouse glioma models. <i>Journal of Neuropathology and Experimental Neurology</i> , 2014 , 73, 1062-77	3.1	14
301	Immunology of brain tumors. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012 , 104, 45-51	3	14
300	Evaluation of drug interactions and dosing in 484 neurological inpatients using clinical decision support software and an extended operational interaction classification system (Zurich Interaction System). <i>Pharmacoepidemiology and Drug Safety</i> , 2011 , 20, 930-8	2.6	14
299	Defective p53 antiangiogenic signaling in glioblastoma. <i>Neuro-Oncology</i> , 2010 , 12, 894-907	1	14
298	Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, LBA2000-LBA2000	2.2	14
297	Predisposing and precipitating factors for delirium in neurology: a prospective cohort study of 1487 patients. <i>Journal of Neurology</i> , 2019 , 266, 3065-3075	5.5	13
296	Epidermal growth factor receptor and ligand family expression and activity in glioblastoma. <i>Journal of Neurochemistry</i> , 2018 , 147, 99-109	6	13
295	Computer-assisted quantification of motile and invasive capabilities of cancer cells. <i>Scientific Reports</i> , 2015 , 5, 15338	4.9	13
294	Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach. <i>Acta Neuropathologica</i> , 2013 , 126, 21-37	14.3	13
293	Drug-related problems and factors influencing acceptance of clinical pharmacologists' alerts in a large cohort of neurology inpatients. <i>Swiss Medical Weekly</i> , 2012 , 142, w13615	3.1	13
292	SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. <i>Neuro-Oncology</i> , 2021 , 23, 1835-1844	1	13

291	Pseudoprogession: fact or wishful thinking in neuro-oncology?. <i>Lancet Oncology, The</i> , 2018 , 19, 1561-1567	6.7	13
290	Defining EGFR amplification status for clinical trial inclusion. <i>Neuro-Oncology</i> , 2019 , 21, 1263-1272	1	12
289	Immunotherapy for glioblastoma: quo vadis?. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 405-406	19.4	12
288	Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway. <i>PLoS ONE</i> , 2013 , 8, e63527	3.7	12
287	Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells. <i>Journal of Neuro-Oncology</i> , 1998 , 37, 191-8	4.8	12
286	CD95-mediated apoptosis: no variation in cellular sensitivity during cell cycle progression. <i>FEBS Letters</i> , 1998 , 432, 155-7	3.8	12
285	Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2007-2007	2.2	12
284	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , 2020 , 22, 601-612	1	12
283	The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , 2019 , 116, 190-198	7.5	11
282	Immunotherapy of Brain Cancer. <i>Oncology Research and Treatment</i> , 2016 , 39, 326-34	2.8	11
281	Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142). <i>Neuro-Oncology</i> , 2011 , 13, 559-60; author reply 561-2	1	11
280	MIP-1alpha antagonizes the effect of a GM-CSF-enhanced subcutaneous vaccine in a mouse glioma model. <i>Journal of Neuro-Oncology</i> , 2004 , 66, 147-54	4.8	11
279	Predisposing and precipitating risk factors for delirium in palliative care patients. <i>Palliative and Supportive Care</i> , 2020 , 18, 437-446	2.5	11
278	Genetic variants of homocysteine metabolism and multiple sclerosis: a case-control study. <i>Neuroscience Letters</i> , 2014 , 562, 75-8	3.3	10
277	ATPS-73BIOLOGICAL ACTIVITY OF TUMOR-TREATING FIELDS (TFIELDS) IN GLIOMA MODELS IN A PRECLINICAL SETTING. <i>Neuro-Oncology</i> , 2015 , 17, v34.3-v34	1	10
276	Does cilengitide deserve another chance?-Authors' reply. <i>Lancet Oncology, The</i> , 2014 , 15, e585-e586	21.7	10
275	Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). <i>Journal of Neuro-Oncology</i> , 2011 , 104, 801-9	4.8	10
274	Classification and management of anaplastic gliomas. <i>Current Opinion in Neurology</i> , 2009 , 22, 650-6	7.1	10

273	Retroviral BAX gene transfer fails to sensitize malignant glioma cells to CD95L-induced apoptosis and cancer chemotherapy. <i>International Journal of Cancer</i> , 1998 , 77, 645-8	7.5	10
272	Cellular stimulation via CD95 involves activation of phospho-inositide-3-kinase. <i>Pflugers Archiv European Journal of Physiology</i> , 1998 , 435, 546-54	4.6	10
271	CD95 ligand-induced apoptosis of human medulloblastoma cells. <i>Cancer Letters</i> , 1998 , 128, 121-6	9.9	10
270	Mechanisms of apoptosis in central nervous system tumors: application to theory. <i>Current Neurology and Neuroscience Reports</i> , 2002 , 2, 246-53	6.6	10
269	Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2023-2023	2.2	10
268	Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid. <i>PLoS ONE</i> , 2014 , 9, e94921	3.7	10
267	Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. <i>Oncotarget</i> , 2016 , 7, 81995-82012	3.3	10
266	Leukoencephalopathy after prophylactic whole-brain irradiation with or without hippocampal sparing: a longitudinal magnetic resonance imaging analysis. <i>European Journal of Cancer</i> , 2020 , 124, 194-203	7.5	10
265	Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 659-670	4.9	10
264	Neurological complications of cancer immunotherapy. <i>Cancer Treatment Reviews</i> , 2021 , 97, 102189	14.4	10
263	INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS. <i>Neuro-Oncology</i> , 2019 , 21, vi137-vi137	1	10
262	Treatment Monitoring of Immunotherapy and Targeted Therapy Using F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 464-470	8.9	10
261	Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis. <i>Acta Neuropathologica</i> , 2017 , 134, 905-922	14.3	9
260	CHD7 promotes glioblastoma cell motility and invasiveness through transcriptional modulation of an invasion signature. <i>Scientific Reports</i> , 2019 , 9, 3952	4.9	9
259	Glioblastoma in the elderly: making sense of the evidence. <i>Neuro-Oncology Practice</i> , 2016 , 3, 77-86	2.2	9
258	LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410. <i>Neuro-Oncology</i> , 2017 , 19, vi316-vi316	1	9
257	Interferon- γ Modulates the Innate Immune Response against Glioblastoma Initiating Cells. <i>PLoS ONE</i> , 2015 , 10, e0139603	3.7	9
256	Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma. <i>Chemotherapy</i> , 2014 , 60, 375-8	3.2	9

255	Treosulfan chemotherapy for recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2000 , 49, 231-4	4.8	9
254	Do host factors determine long-term survival in glioblastoma? A genome/transcriptome profiling study by the German Glioma Network.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2014-2014	2.2	9
253	Determining medical decision-making capacity in brain tumor patients: why and how?. <i>Neuro-Oncology Practice</i> , 2020 , 7, 599-612	2.2	9
252	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. <i>Acta Neuropathologica</i> , 2021 , 141, 945-957	14.3	9
251	Subacute cerebellar ataxia following respiratory symptoms of COVID-19: a case report. <i>BMC Infectious Diseases</i> , 2021 , 21, 298	4	9
250	Contraceptive drugs mitigate experimental stroke-induced brain injury. <i>Cardiovascular Research</i> , 2019 , 115, 637-646	9.9	9
249	Anticonvulsive effect of anterior thalamic deep brain stimulation in super-refractory status epilepticus crucially depends on active stimulation zone-A single case observation. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2019 , 71, 286-288	3.2	8
248	Where does O ⁶ -methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma?. <i>Cancer</i> , 2018 , 124, 1316-1318	6.4	8
247	Boswellic acid activity against glioblastoma stem-like cells. <i>Oncology Letters</i> , 2016 , 11, 4187-4192	2.6	8
246	Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. <i>Neuro-Oncology</i> , 2019 , 21, 234-241	1	8
245	The legend of cytomegalovirus and glioblastoma lives on. <i>Neuro-Oncology</i> , 2014 , 16, 166	1	8
244	Management of diffusely infiltrating glioma in the elderly. <i>Current Opinion in Oncology</i> , 2015 , 27, 502-9	4.2	8
243	Addition of lomustine for bevacizumab-refractory recurrent glioblastoma. <i>Acta Oncologica</i> , 2014 , 53, 1436-40	3.2	8
242	The vanishing role of whole brain radiotherapy for primary central nervous system lymphoma. <i>Neuro-Oncology</i> , 2014 , 16, 1035-6	1	8
241	Angiogenesis in glioblastoma: just another moving target?. <i>Brain</i> , 2010 , 133, 955-6	11.2	8
240	Glioma tropism of lentivirally transduced hematopoietic progenitor cells. <i>International Journal of Oncology</i> , 2010 , 36, 1409-17	4.4	8
239	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3839-3852	2.2	8
238	An engineered 4-1BBL fusion protein with "activity on demand". <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 31780-31788	11.5	8

237	Current State of Immune-Based Therapies for Glioblastoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, e132-9	7.1	8
236	Risk factors for the development of epilepsy in patients with brain metastases. <i>Neuro-Oncology</i> , 2020 , 22, 718-728	1	8
235	Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter.. <i>Neuro-Oncology</i> , 2022 ,	1	8
234	Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. <i>European Journal of Cancer</i> , 2018 , 101, 95-104	7.5	7
233	Complementary and alternative medicine use in glioma patients in France. <i>Journal of Neuro-Oncology</i> , 2019 , 145, 487-499	4.8	7
232	Differential expression of the tumor suppressor A-kinase anchor protein 12 in human diffuse and pilocytic astrocytomas is regulated by promoter methylation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013 , 72, 933-41	3.1	7
231	Malignant astrocytoma in elderly patients: where do we stand?. <i>Current Opinion in Neurology</i> , 2013 , 26, 693-700	7.1	7
230	Are we ready to demystify age in glioblastoma? Or does older age matter in glioblastoma?. <i>Neuro-Oncology</i> , 2011 , 13, 365-6	1	7
229	Monitoring the glioma tropism of bone marrow-derived progenitor cells by 2-photon laser scanning microscopy and positron emission tomography. <i>Neuro-Oncology</i> , 2012 , 14, 471-81	1	7
228	Soluble CD95 (Fas/APO-1) in malignant glioma: (no) implications for CD95-based immunotherapy?. <i>Journal of Neuro-Oncology</i> , 1998 , 40, 233-5	4.8	7
227	Synergy of CD95 ligand and teniposide: no role of cleavable complex formation and enhanced CD95 expression. <i>European Journal of Pharmacology</i> , 1998 , 341, 323-8	5.3	7
226	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2001-2001	2.2	7
225	Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, LBA2000-LBA2000	2.2	7
224	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. <i>Cancer Medicine</i> , 2020 , 9, 8373-8385	4.8	7
223	Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. <i>Radiology</i> , 2020 , 297, 164-175	20.5	7
222	Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma. <i>ESMO Open</i> , 2020 , 5,	6	7
221	Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma. <i>Neuro-Oncology</i> , 2020 , 22, 1742-1756	1	7
220	Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype. <i>Nature Communications</i> , 2020 , 11, 6434	17.4	7

219	Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression. <i>ACS Central Science</i> , 2021 , 7, 868-881	16.8	7
218	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. <i>Neuro-Oncology</i> , 2021 , 23, 1547-1559	1	7
217	How we treat patients with brain tumour during the COVID-19 pandemic. <i>ESMO Open</i> , 2020 , 4, e000789	6	7
216	Complementary and alternative medicine use by glioma patients in Switzerland. <i>Neuro-Oncology Practice</i> , 2019 , 6, 237-244	2.2	7
215	Preparation of PEGylated liposomes incorporating lipophilic lomeguatrib derivatives for the sensitization of chemo-resistant gliomas. <i>International Journal of Pharmaceutics</i> , 2018 , 536, 388-396	6.5	7
214	Post-operative cardiovascular complications and time to recurrence in meningioma patients treated with versus without pre-operative embolization: a retrospective cohort study of 741 patients. <i>Journal of Neuro-Oncology</i> , 2018 , 140, 659-667	4.8	7
213	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. <i>Neurology</i> , 2019 , 92, e2754-e2763	6.5	6
212	Neurology--the next 10 years. <i>Nature Reviews Neurology</i> , 2015 , 11, 658-64	15	6
211	Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?. <i>Current Opinion in Neurology</i> , 2020 , 33, 701-706	7.1	6
210	Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study. <i>Journal of Neuro-Oncology</i> , 2020 , 148, 117-130	4.8	6
209	Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR Phosphorylation. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1328-1339	6.1	6
208	Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9. <i>Neuro-Oncology</i> , 2019 , 21, 1607-1609	1	6
207	136 Complete Resection of Contrast-Enhancing Tumor Volume is Associated With Improved Survival in Recurrent Glioblastoma Results From the DIRECTOR Trial. <i>Neurosurgery</i> , 2015 , 62, 209	3.2	6
206	The management of lomustine overdose in malignant glioma patients. <i>Neuro-Oncology Practice</i> , 2014 , 1, 178-183	2.2	6
205	Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 872-80	2.6	6
204	p53 Accumulation Promotes Dephosphorylation and Proteolytic Cleavage of Retinoblastoma Protein in Human Malignant Glioma Cells. <i>Cellular Physiology and Biochemistry</i> , 1997 , 7, 304-311	3.9	6
203	Hypoxia sensitizes human malignant glioma cells towards CD95L-induced cell death. <i>Journal of Neurochemistry</i> , 2005 , 92, 1340-9	6	6
202	Genetic Regulation and Therapeutic Modulation of Apoptosis in Human Malignant Glioma. <i>Cellular Physiology and Biochemistry</i> , 1996 , 6, 376-380	3.9	6

201	Effect of the integrin inhibitor cilengitide on TGF-beta signaling.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2055-2055	2.2	6
200	Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas. <i>Oncotarget</i> , 2017 , 8, 87124-87135	3.3	6
199	Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. <i>The Lancet Digital Health</i> , 2021 , 3, e784-e794	14.4	6
198	Does Neuronal Activity Promote Glioma Progression?. <i>Trends in Cancer</i> , 2020 , 6, 1-3	12.5	6
197	Crossed Cerebellar Diaschisis in Patients with Diffuse Glioma Is Associated with Impaired Supratentorial Cerebrovascular Reactivity and Worse Clinical Outcome. <i>Cerebellum</i> , 2020 , 19, 824-832	4.3	6
196	ACTR-39. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE. <i>Neuro-Oncology</i> , 2019 , 21, vi21-vi22	1	6
195	Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.. <i>Neuro-Oncology</i> , 2022 ,	1	6
194	Management of Elderly Patients with Glioblastoma. <i>Current Neurology and Neuroscience Reports</i> , 2017 , 17, 35	6.6	5
193	Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial. <i>Neurology</i> , 2019 , 93, e1799-e1806	6.5	5
192	New insights into acquired temozolomide resistance in glioblastoma?. <i>Brain</i> , 2015 , 138, 3468-70	11.2	5
191	Socioeconomic burden and quality of life in meningioma patients. <i>Quality of Life Research</i> , 2020 , 29, 1803-1808	5.7	5
190	Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018 , 365, 422-429	4.7	5
189	Next generation neuro-oncology. <i>European Journal of Cancer</i> , 2018 , 96, 1-5	7.5	5
188	Reciprocal modulation of Aβ2 aggregation by copper and homocysteine. <i>Frontiers in Aging Neuroscience</i> , 2014 , 6, 237	5.3	5
187	Whole-brain radiotherapy in primary CNS lymphoma [Authors' reply. <i>Lancet Oncology</i> , 2011 , 12, 119-120	21.7	5
186	Characterization of daunorubicin-induced apoptosis in retinal pigment epithelial cells: modulation by CD95L. <i>Investigative Ophthalmology and Visual Science</i> , 2003 , 44, 2851-7		5
185	EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS2072-TPS2072	2.2	5
184	Primary Tumors of the Central and Peripheral Nervous System 2003 , 827-863		5

183	EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2004-2004	2.2	5
182	MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 179-188	12.9	5
181	Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF- β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab058	0.9	5
180	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. <i>Acta Neuropathologica</i> , 2018 , 136, 975-978	14.3	5
179	The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. <i>European Journal of Cancer</i> , 2021 , 156, 93-108	7.5	5
178	Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. <i>Neuro-Oncology</i> , 2020 , 22, 1667-1676	1	4
177	Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. <i>European Journal of Cancer</i> , 2020 , 135, 150-158	7.5	4
176	Evidence-based management of adult patients with diffuse glioma - Authors' reply. <i>Lancet Oncology, The</i> , 2017 , 18, e430-e431	21.7	4
175	Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply. <i>Lancet Oncology, The</i> , 2017 , 18, e709-e710	21.7	4
174	Factor V Leiden as a cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis?. <i>Annals of Neurology</i> , 1998 , 44, 426-7	9.4	4
173	MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2015-2015	2.2	4
172	Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet!. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1829-30	2.2	4
171	ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION. <i>Neuro-Oncology</i> , 2019 , 21, vi14-vi14	1	4
170	FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. <i>Acta Neuropathologica</i> , 2020 , 139, 175-192	14.3	4
169	Hemodynamic investigation of peritumoral impaired blood oxygenation-level dependent cerebrovascular reactivity in patients with diffuse glioma. <i>Magnetic Resonance Imaging</i> , 2020 , 70, 50-56	3.3	4
168	A vasculature-centric approach to developing novel treatment options for glioblastoma. <i>Expert Opinion on Therapeutic Targets</i> , 2021 , 25, 87-100	6.4	4
167	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4
166	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4

165	Venous thromboembolic events in patients with brain metastases: the PICOS score. <i>European Journal of Cancer</i> , 2020 , 134, 75-85	7.5	3
164	Burnout and career satisfaction in neuro-oncology: a survey of the Society for Neuro-Oncology and the European Association of Neuro-Oncology memberships. <i>Neuro-Oncology</i> , 2020 , 22, 838-850	1	3
163	End-of-life care for glioma patients; the caregivers' perspective. <i>Journal of Neuro-Oncology</i> , 2020 , 147, 663-669	4.8	3
162	In search of cerebrospinal fluid biomarkers of fatigue in multiple sclerosis: A proteomics study. <i>Journal of Sleep Research</i> , 2019 , 28, e12721	5.8	3
161	Movement disorders reveal Creutzfeldt-Jakob disease. <i>Nature Reviews Neurology</i> , 2009 , 5, 185-6	15	3
160	Determining the glioma CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2017-2017	2.2	3
159	Long-term survival in patients with primary CNS lymphoma: Results from the G-PCNSL-SG1 trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2032-2032	2.2	3
158	EGFR gene amplification and variant III (EGFRvIII) mutation in primary and recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2042-2042	2.2	3
157	GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS2579-TPS2579	2.2	3
156	CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548. <i>Neuro-Oncology</i> , 2021 , 23, vi55-vi56	1	3
155	Novel cases of amyotrophic lateral sclerosis after treatment of cerebral arteriovenous malformations. <i>Swiss Medical Weekly</i> , 2016 , 146, w14361	3.1	3
154	A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. <i>Swiss Medical Weekly</i> , 2020 , 150, w20256	3.1	3
153	Sex-specific aspects of epidemiology, molecular genetics and outcome: primary brain tumours. <i>ESMO Open</i> , 2020 , 5, e001034	6	3
152	Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models. <i>Journal of Neurochemistry</i> , 2020 , 153, 510-524	6	3
151	Telomerase reverse transcriptase promoter mutation- and O-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?. <i>European Journal of Cancer</i> , 2021 , 147, 84-94	7.5	3
150	ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. <i>Neuro-Oncology</i> , 2019 , 21, vi12-vi12	1	3
149	Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses 1998 , 79, 640		3
148	Meeting Update-World Federation of Neuro-Oncology Societies (WFNOS) Meeting 2017. <i>Neuro-Oncology</i> , 2017 , 19, 1457-1459	1	2

147	Underweight and weight loss are predictors of poor outcome in patients with brain metastasis. <i>Journal of Neuro-Oncology</i> , 2019 , 145, 339-347	4.8	2
146	Reply to glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. <i>Cancer</i> , 2016 , 122, 3740-3741	6.4	2
145	An Enzyme- and Serum-free Neural Stem Cell Culture Model for EMT Investigation Suited for Drug Discovery. <i>Journal of Visualized Experiments</i> , 2016 ,	1.6	2
144	Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities. <i>Public Health Genomics</i> , 2016 , 19, 170-7	1.9	2
143	Bevacizumab failure in glioblastomas.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2067-2067	2.2	2
142	Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2092-2092	2.2	2
141	G-PCNSL-SG-1 randomized phase III trial of high-dose methotrexate with or without whole brain radiotherapy for primary central nervous system lymphoma: Long-term follow-up.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8527-8527	2.2	2
140	Interferon- β sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02. <i>Oncology Letters</i> , 2020 , 19, 2649-2656	2.6	2
139	Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials. <i>Clinical Cancer Research</i> , 2021 ,	12.9	2
138	Adjuvant therapy. <i>Recent Results in Cancer Research</i> , 2009 , 171, 141-53	1.5	2
137	Overall patient survival of glioblastoma associated to molecular markers: a pan-proteomic prospective study		2
136	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation: Final results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1512-1522	2.2	2
135	Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. <i>Neuro-Oncology Practice</i> , 2020 , 7, 668-675	2.2	2
134	Antidepressant drug use in glioblastoma patients: an epidemiological view. <i>Neuro-Oncology Practice</i> , 2020 , 7, 514-521	2.2	2
133	Distinct Cerebrovascular Reactivity Patterns for Brain Radiation Necrosis. <i>Cancers</i> , 2021 , 13,	6.6	2
132	Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. <i>European Journal of Cancer</i> , 2021 , 147, 1-12	7.5	2
131	Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment		2
130	Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion		2

129	Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma. <i>Cancers</i> , 2021 , 13,	6.6	2
128	Development of Randomized Trials in Adults with Medulloblastoma-The Example of EORTC 1634-BTG/NOA-23. <i>Cancers</i> , 2021 , 13,	6.6	2
127	Hypermetabolism and impaired cerebrovascular reactivity beyond the standard MRI-identified tumor border indicate diffuse glioma extended tissue infiltration. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab048	0.9	2
126	ATIM-16. PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM). <i>Neuro-Oncology</i> , 2018 , 20, vi4-vi4	1	2
125	The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma. <i>Cell Death and Disease</i> , 2021 , 12, 885	9.8	2
124	Endoglin and TGF- β signaling in glioblastoma. <i>Cell and Tissue Research</i> , 2021 , 384, 613-624	4.2	2
123	A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.. <i>EMBO Molecular Medicine</i> , 2022 , e14552	12	2
122	Hemodynamic Imaging in Cerebral Diffuse Glioma-Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions.. <i>Cancers</i> , 2022 , 14,	6.6	2
121	Glioblastoma 2017 , 265-288		1
120	Impaired speed-dependent modulation of the gait pattern in multiple sclerosis. <i>Journal of Neurology</i> , 2020 , 267, 2998-3007	5.5	1
119	Reply to F. Felix et al and M.F. Fay et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3107-8	2.2	1
118	Letter to the Editor. Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma. <i>Journal of Neurosurgery</i> , 2018 , 129, 1104-1105	3.2	1
117	Brain Tumor Imaging. <i>Medical Radiology</i> , 2015 , 1-9	0.2	1
116	ATNT-10DOES VALPROIC ACID IMPROVE SURVIVAL IN GLIOBLASTOMA? A META-ANALYSIS OF RANDOMIZED TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015 , 17, v12.2-v12	1	1
115	Elderly people with glioblastoma Authors' reply. <i>Lancet Oncology, The</i> , 2012 , 13, e329	21.7	1
114	Systemic Relapses In Primary CNS Lymphoma (PCNSL) - Unexpected Clonal Diversity. <i>Blood</i> , 2010 , 116, 3125-3125	2.2	1
113	Postranslationally Modified Proteins in the Central Nervous System (CNS) Are the Dominant Antigenic Target/Stimulus of the B-Cell Receptor (BCR) in Primary CNS Lymphomas (PCNSL) Providing Strong Evidence for the Role of Chronic Autoantigenic Stimulation As an Early Step in the Pathogenesis of Aggressive B-Cell Lymphomas. <i>Blood</i> 2014 , 124, 142-142	2.2	1
112	MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2000-2000	2.2	1

111	Prognostic value of 18FET positron emission tomography (18FET-PET) for the clinical course in newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2045-2045	2.2	1
110	Evaluation of invasion patterns and their correlation with integrin alphavbeta expression in brain metastases of solid cancers.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2059-2059	2.2	1
109	Molecular classification of diffuse cerebral gliomas using genome- and transcriptome-wide profiling.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2007-2007	2.2	1
108	Glioblastoma in the Canton of Zurich, Switzerland, revisited (2005-2009).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e13025-e13025	2.2	1
107	Correlation of IDH mutation, 1p/19q co-deletion and 18FET-PET derived time-to-peak analysis as prognostic markers in glioma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2058-2058	2.2	1
106	Clinical and molecular subgroups of ependymoma in adulthood: An analysis of the German Glioma Network.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2038-2038	2.2	1
105	Barriers to accrual and enrollment in brain tumor trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2024-2024	2.2	1
104	Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2056-2056	2.2	1
103	Estimated clinical efficacy and radiographic response characteristics of PD1 inhibition in newly diagnosed and recurrent glioblastoma in clinical practice: A report from the iRANO Working Group.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2521-2521	2.2	1
102	The HLA Ligand Atlas: A novel immuno-oncology resource for T-cell antigen discovery.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3128-3128	2.2	1
101	Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2021 ,	1	1
100	Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma. <i>Hematology/Oncology Clinics of North America</i> , 2022 , 36, 113-132	3.1	1
99	Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa147	0.9	1
98	Role of Integrins in Angiogenesis 2013 , 79-91		1
97	32. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING AMINO ACID PET IN PATIENTS WITH BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2020 , 2, ii5-ii6	0.9	1
96	Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. <i>Translational Oncology</i> , 2020 , 13, 100852	4.9	1
95	Response to Letter to Editor. <i>Neuro-Oncology</i> , 2020 , 22, 1706-1707	1	1
94	Negative allosteric modulators of metabotropic glutamate receptor 3 target the stem-like phenotype of glioblastoma. <i>Molecular Therapy - Oncolytics</i> , 2021 , 20, 166-174	6.4	1

93	Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial. <i>Frontiers in Oncology</i> , 2021 , 11, 636672	5.3	1
92	PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. <i>Journal of Neuro-Oncology</i> , 2021 , 153, 283-291	4.8	1
91	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS2074-TPS2074	2.2	1
90	Vaccination for IDH-mutant tumors: A novel therapeutic approach applied to glioma.. <i>Med</i> , 2021 , 2, 450-457	3.7	1
89	ACTR-30. EORTC 1608: A PHASE 1B STUDY OF TG02, AN ORAL CYCLIN-DEPENDENT KINASE 9/5 INHIBITOR, IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA STRATIFIED BY MGMT PROMOTER METHYLATION STATUS. <i>Neuro-Oncology</i> , 2016 , 18, vi8-vi8	1	1
88	ACTR-04. RESULTS OF THE INTERIM ANALYSIS OF THE EORTC RANDOMIZED PHASE III CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CO-DELETION, AN INTERGROUP TRIAL. <i>Neuro-Oncology</i> , 2016 , 18, vi1-vi2	1	1
87	The molecular evolution of glioblastoma treated by gross total resection alone. <i>Neuro-Oncology</i> , 2021 , 23, 334-336	1	1
86	IMMU-53. IMPACT OF TUMOR-TREATING FIELDS (TTFIELDS) ON THE IMMUNOGENICITY OF GLIOMA CELLS. <i>Neuro-Oncology</i> , 2018 , 20, vi133-vi133	1	1
85	RARE-19. CHEMOTHERAPY FOR SPINAL GLIOMAS IN ADULTS: A RETROSPECTIVE STUDY. <i>Neuro-Oncology</i> , 2018 , 20, vi240-vi240	1	1
84	CMET-39. INTRA-CSF LIPOSOMAL CYTARABINE PLUS SYSTEMIC THERAPY AS INITIAL TREATMENT OF BREAST CANCER LEPTOMENINGEAL METASTASIS: A RANDOMISED, OPEN-LABEL TRIAL. <i>Neuro-Oncology</i> , 2018 , 20, vi61-vi62	1	1
83	ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON DEPATUX ^M ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA (NCT02343406). <i>Neuro-Oncology</i> , 2018 , 20, vi20-vi20	1	1
82	The epigenetic evolution of gliomas is determined by their IDH1 mutation status and treatment regimen		1
81	DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients.. <i>Acta Neuropathologica Communications</i> , 2022 , 10, 39	7.3	1
80	Opportunities and Challenges for the development of 'Core Outcome Sets' in Neuro-Oncology.. <i>Neuro-Oncology</i> , 2022 ,	1	1
79	Feasibility of glioblastoma tissue response mapping with physiologic BOLD imaging using precise oxygen and carbon dioxide challenge. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2021 , 35, 29	2.8	1
78	Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors. <i>MAbs</i> , 2020 , 12, 1836713	6.6	0
77	Nanomania ante portas of neurooncology?. <i>Journal of Neuro-Oncology</i> , 2011 , 104, 613-614	4.8	0
76	Bevacizumab plus radiotherapy for elderly patients with glioblastoma (ARTE).. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS2105-TPS2105	2.2	0

75	NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT. <i>Neuro-Oncology</i> , 2021 , 23, vi126-vi127	1	○
74	Single cell mapping of human brain tumors reveals tumor-specific education of tissue-invading leukocytes.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2509-2509	2.2	○
73	A tumor-promoting role for soluble TRIM39 in glioblastoma. <i>Molecular and Cellular Biochemistry</i> , 2021 , 476, 2963-2973	4.2	○
72	Pathway-based stratification of glioblastoma. <i>Nature Reviews Neurology</i> , 2021 , 17, 263-264	15	○
71	Cancer is associated with inferior outcome in patients with ischemic stroke. <i>Journal of Neurology</i> , 2021 , 268, 4190-4202	5.5	○
70	Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM). <i>Swiss Medical Weekly</i> , 2021 , 151, w20501	3.1	○
69	QOLP-03. MEASURING CHANGE IN HEALTH-RELATED QUALITY OF LIFE: THE ADDED VALUE OF ANALYSIS ON THE INDIVIDUAL PATIENT LEVEL IN GLIOMA PATIENTS IN CLINICAL DECISION MAKING. <i>Neuro-Oncology</i> , 2019 , 21, vi197-vi198	1	○
68	LTBK-12. EORTC 26951, RANDOMIZED STUDY OF ADJUVANT PCV AFTER 59.4 GY RADIOTHERAPY: VERY LONG TERM FOLLOW-UP. <i>Neuro-Oncology</i> , 2019 , 21, vi285-vi285	1	○
67	Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. <i>Neuro-Oncology Practice</i> , 2021 , 8, 417-425	2.2	○
66	Radiotherapy for glioblastoma patients with poor performance status. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 1	4.9	○
65	Economic Impact of Poststroke Delirium and Associated Risk Factors: Findings From a Prospective Cohort Study. <i>Stroke</i> , 2021 , 52, 3325-3334	6.7	○
64	mA Regulator Expression Segregates Meningiomas Into Biologically Distinct Subtypes.. <i>Frontiers in Oncology</i> , 2021 , 11, 760892	5.3	○
63	Development of 'Core Outcome Sets' for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings.. <i>BMJ Open</i> , 2022 , 12, e057384	3	○
62	Immuntherapie von Hirntumoren. <i>Aktuelle Neurologie</i> , 2017 , 44, 400-408		
61	Concepts of Personalized Medicine in Neuro-oncology 2019 , 153-158		
60	Glioblastoma 2019 , 237-247		
59	Basics of Brain Tumor Biology for Clinicians 2019 , 7-19		
58	Interferon-β exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa043	0.9	○

57	Gender issues from the perspective of health-care professionals in Neuro-oncology: an EANO and EORTC Brain Tumor Group survey. <i>Neuro-Oncology Practice</i> , 2020 , 7, 249-259	2.2
56	DRES-13. EXTENDED TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK. <i>Neuro-Oncology</i> , 2016 , 18, vi54-vi54	1
55	Was sind niedriger-gradige Gliome?. <i>InFo Neurologie & Psychiatrie</i> , 2015 , 17, 35-35	0
54	Drei molekulare Marker für Hauptgruppen. <i>InFo Neurologie & Psychiatrie</i> , 2015 , 17, 32-32	0
53	MicroRNAs in Primary Brain Tumors: Functional Impact and Potential Use for Diagnostic Purposes 2014 , 25-38	
52	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2010 , 28, e696-e697	2.2
51	Molekular definierte Chemotherapien und zielgerichtete Therapien bei malignen Gliomen. <i>Onkopipeline</i> , 2008 , 1, 11-16	
50	Apoptosis Pathways and Chemotherapy 2006 , 141-154	
49	Exploiting Apoptosis Pathways for Glioblastoma Therapy 1033-1048	
48	Effective suppression of crescendo amaurosis fugax associated with anti-phospholipid antibodies by low dose aspirin. <i>Neuro-Ophthalmology</i> , 1991 , 11, 195-197	0.9
47	Die WHO-Klassifikation der Tumoren des zentralen Nervensystems 2021. <i>Onkologe</i> , 2022 , 28, 155-163	0.1
46	CSIG-17. IMMUNE MODULATORY ROLE OF TYPE I INTERFERON IN SYNGENEIC MOUSE GLIOMA MODELS. <i>Neuro-Oncology</i> , 2021 , 23, vi36-vi37	1
45	DDRE-21. LOMUSTINE AND TARGETED-CYTOKINE THERAPY: A BENEFICIAL LIAISON FOR RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021 , 23, vi78-vi79	1
44	EPCO-09. LONGITUDINAL ANALYSIS OF DIFFUSE GLIOMA REVEALS CELL STATE DYNAMICS AT RECURRENCE ASSOCIATED WITH CHANGES IN GENETICS AND THE MICROENVIRONMENT. <i>Neuro-Oncology</i> , 2021 , 23, vi3-vi3	1
43	IMMU-13. COMBINED MODULATION OF THE TGF- β PATHWAY AND GITR IMMUNE CHECKPOINT SIGNALING PROMOTES ANTI-TUMOR IMMUNITY IN SYNGENEIC GLIOMA MODELS. <i>Neuro-Oncology</i> , 2021 , 23, vi94-vi94	1
42	IMMU-39. EVALUATION OF CD317-TARGETING CAR T CELLS AS A NOVEL IMMUNOTHERAPEUTIC STRATEGY AGAINST GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021 , 23, vi101-vi101	1
41	EXTH-21. MECHANISMS OF SYNERGISTIC GROWTH SUPPRESSION BY RADIOTHERAPY AND C-MET INHIBITION IN EXPERIMENTAL GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021 , 23, vi167-vi168	1
40	CSIG-22. Cd95l/Cd95 GENE DELETION DECREASES MOUSE GLIOMA TUMORIGENESIS THROUGH THE INHIBITION OF NON-CANONICAL CD95L/CD95-MEDIATED CELL GROWTH AND IMMUNOSUPPRESSION. <i>Neuro-Oncology</i> , 2021 , 23, vi37-vi38	1

- 39 PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED. *Neuro-Oncology*, **2021**, 23, vi123-vi124 1
- 38 Death Ligand/Death Receptor-Mediated Apoptosis for Treatment of Brain Tumors **2001**, 327-344
- 37 Modulating TGF- β Receptor Signaling: A Novel Approach of Cancer Therapy **2008**, 653-669
- 36 CNS Tumors in Older Adults **2018**, 1-9
- 35 Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma.. *Journal of Clinical Oncology*, **2018**, 36, 2013-2013 2.2
- 34 Sensitization of glioblastoma to alkylating chemotherapy by ultrasound-mediated delivery of therapeutic liposomes.. *Journal of Clinical Oncology*, **2018**, 36, e14061-e14061 2.2
- 33 Secondary prophylaxis with romiplostim for temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma.. *Journal of Clinical Oncology*, **2018**, 36, 2042-2042 2.2
- 32 Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.. *Journal of Clinical Oncology*, **2018**, 36, e14070-e14070 2.2
- 31 Glioblastoma in the era of bevacizumab: An epidemiological study in the Canton of Zurich, Switzerland, 2010-2014.. *Journal of Clinical Oncology*, **2018**, 36, e14062-e14062 2.2
- 30 Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.. *Journal of Clinical Oncology*, **2019**, 37, 2013-2013 2.2
- 29 Treatment of Leptomeningeal Metastases **2020**, 301-311
- 28 CNS Tumors in Older Adults **2020**, 813-821
- 27 Venous thromboembolic events in glioblastoma patients: Common complication but not a major reason for death.. *Journal of Clinical Oncology*, **2020**, 38, e14530-e14530 2.2
- 26 Gliome des Erwachsenenalters. *Springer Reference Medizin*, **2021**, 1-12 0
- 25 Hirntumoren **2015**, 609-619
- 24 Does extent of resection matter in recurrent glioblastoma? Lessons from the DIRECTOR trial.. *Journal of Clinical Oncology*, **2015**, 33, 2041-2041 2.2
- 23 Intravenous vs. intra-arterial methotrexate-based chemotherapy regimens for newly diagnosed primary central nervous system lymphoma.. *Journal of Clinical Oncology*, **2016**, 34, e13505-e13505 2.2
- 22 The value of ¹⁸F-fluorodesoxyglucose positron emission tomography (FDG-PET/CT) in the detection of the primary lesion and for staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS).. *Journal of Clinical Oncology*, **2017**, 35, 2076-2076 2.2

21	Quantifying the benefit of chemotherapy and radiation in low-grade glioma: A systematic review and meta-analysis of numbers needed to treat.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2057-2057	2.2
20	Elderly patients with primary CNS lymphoma: Results from the G-PCNSL-SG-1 trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2007-2007	2.2
19	Long-term survival in primary glioblastoma revisited: The contribution of isocitrate dehydrogenase mutations.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2027-2027	2.2
18	Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma (DIRECTOR).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS2103-TPS2103	2.2
17	Effect of silencing thymosin beta 4 gene expression on stemness and invasiveness in glioblastoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2081-2081	2.2
16	Induction of atypical anoikis in glioma cells through inhibition of integrin functions.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2079-2079	2.2
15	Appropriate Analysis of Duration of Response Data in Cancer Trials-Reply. <i>JAMA Oncology</i> , 2020 , 6, 1978-1979	3.2
14	Prognostic value of O-(2-[F]-fluoroethyl)-L-tyrosine PET in relapsing oligodendroglioma. <i>Acta Oncologica</i> , 2020 , 59, 1357-1364	3.2
13	DEPOSEIN-how meaningful was the benefit from intrathecal chemotherapy?. <i>Neuro-Oncology</i> , 2020 , 22, 1710-1711	1
12	Chemotherapy for adult patients with spinal cord gliomas. <i>Neuro-Oncology Practice</i> , 2021 , 8, 475-484	2.2
11	Prognostic factors in leptomeningeal metastases. <i>Neuro-Oncology</i> , 2021 , 23, 1208-1209	1
10	Digital measurement of functional status of patients with glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2016-2016	2.2
9	Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression. <i>Neuro-Oncology</i> , 2021 , 23, 1612-1613	1
8	ACTR-18. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: AN UPDATE FROM THE BRAIN TUMOR FUNDERS COLLABORATIVE CONSORTIUM. <i>Neuro-Oncology</i> , 2016 , 18, vi5-vi5	1
7	BMET-18. DIAGNOSIS AND TREATMENT PATTERNS FOR PATIENTS WITH LEPTOMENINGEAL METASTASIS FROM SOLID TUMORS ACROSS EUROPE. <i>Neuro-Oncology</i> , 2016 , 18, vi30-vi30	1
6	Reply: Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels. <i>Brain</i> , 2017 , 140, e17	11.2
5	Drei molekulare Marker für Hauptgruppen. <i>Info Onkologie</i> , 2016 , 19, 26-26	
4	Kindliche Hirntumoren bei Erwachsenen: Medulloblastom. <i>Springer Reference Medizin</i> , 2021 , 1-8	0

3	Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. <i>Neuro-Oncology</i> , 2021 , 23, 506-507	1
2	SYST-03. A PHASE I/II STUDY TO EVALUATE SAFETY AND PRELIMINARY ACTIVITY OF THE TUMOR-TARGETING ANTIBODY-CYTOKINE FUSION PROTEIN L19TNF IN PATIENTS WITH GLIOBLASTOMA AT FIRST RELAPSE. <i>Neuro-Oncology Advances</i> , 2021 , 3, iv8-iv9	0.9
1	Prognosis of walking function in multiple sclerosis supported by gait pattern analysis.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 63, 103802	4